The global Viral Inactivationmarket was valued at USD 320.34million in 2016 and is projected to reach USD 903.43millionby 2025, growing at a CAGR of 12.21% from 2017 to 2025.
This method is one in which the viruses may remain in the final product, but in a non-infective form. The method is highly applicable in modern vaccine development techniques and treatment of other viral diseases involving their study and research. The market is thus expected to grow at a high CAGR.
Sample Infographics:
Market Dynamics:
1. Market Drivers
1.1 Rapid Growth in R&D sector and discoveries
1.2 Increasing fund availability for Biopharmaceutical sector
1.3 Increasing demand for Biopharmaceuticals
1.4 Increasing support from public and private sector
1.5 High Incidence and Large Economic Burden of Chronic Diseases
2. Market Restraints
2.1 High Degree of Consolidation to Act as A Major Barrier for New Entrants
Market Segmentation:
1. By Application:
1.1 Vaccines and Therapeutics
1.2 Blood and Blood Products
1.3 Cellular and Gene Therapy Products
1.4 Tissues and Tissue Products
1.5 Stem Cell Products
2. By End User:
2.1 Pharmaceutical and Biotechnology Companies
2.2 Contract Research Organizations
2.3 Academic Research Institutes
2.4 Other End Users
3. By Product:
3.1 Kits and Reagents
3.2 Services
3.3 Viral Inactivation Systems and Accessories
4. By Region:
4.1 North America (U.S., Canada, Mexico)
4.2 Europe (Germany, UK, France, Rest of Europe)
4.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
4.4 Latin America (Brazil, Argentina, Rest of Latin America)
4.5 Middle East & Africa
Competitive Landscape:
The major players in the market are as follows:
1. Danaher Corporation
2. Merck KGAA
3. Parker Hannifin Corporation
4. Sartorius AG
5. SGS SA
6. Charles River Laboratories International, Inc.
7. Clean Cells Inc.
8. Rad Source Technologies, Inc.
9. Texcell, Inc.
10. Viral Inactivated Plasma Systems SA
11. Wuxi Pharmatech (Cayman) Inc.
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the Viral Inactivationmarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
1 INTRODUCTION OF GLOBAL VIRAL INACTIVATION MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
4 GLOBAL VIRAL INACTIVATIONMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL VIRAL INACTIVATION MARKET,BY APPLICATION
5.1 Vaccines and Therapeutics
5.2 Blood and Blood Products
5.3 Cellular and Gene Therapy Products
5.4 Tissues and Tissue Products
5.5 Stem Cell Products
6 GLOBAL VIRAL INACTIVATION MARKET, BY END USER
6.1 Pharmaceutical and Biotechnology Companies
6.2 Contract Research Organizations
6.3 Academic Research Institutes
6.4 Other End Users
7 GLOBAL VIRAL INACTIVATION MARKET, BY PRODUCT
7.1 Kits and Reagents
7.2 Services
7.3 Viral Inactivation Systems and Accessories
8 GLOBAL VIRAL INACTIVATIONMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025
9 GLOBAL VIRAL INACTIVATIONMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies
10 COMPANY PROFILES
10.1 Danaher Corporation
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
10.2 Merck KGAA
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments
10.3 Parker Hannifin Corporation
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments
10.4 Sartorius AG
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments
10.5 SGS SA
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments
10.6 Charles River Laboratories International, Inc.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments
10.7 Clean Cells Inc.
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments
10.8 Rad Source Technologies, Inc.
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments
10.9 Texcell, Inc.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Development
10.10 Viral Inactivated Plasma Systems SA
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Development
10.11 Wuxi Pharmatech (Cayman) Inc.
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Development
11 Appendix
11.1 Related Reports
The Viral Vector Manufacturing for Gene Therapy Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive la...
The Viral Vector Packaging Services Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, man...
Overview of the Global GMP Viral Vector Manufacturing Market :
The report discusses everything a marketer requires before investing in the global GMP Viral Vector Manufacturing Market during the forecast period 202...
Overview of the Global Viral Vector CDMO Services Market:
The report discusses everything a marketer requires before investing in the global Viral Vector CDMO Services Market during the forecast period 2023-2030. It...
The global Viral Transport Media market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in thi...
The global Viral Transport Kit market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this ...
Description
The global Agricultural Lubricants Market will reach 1.72 million tons by 2029, with a 2.4% CAGR from 2023 to 2029. Government subsidies for farm machinery in India and China, along with increasing farm mechanization, drive growth. High costs of synthetic and bio-based lubricants h...
The global Viral Vaccine Media market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this ...
The global Viral Pneumonia Treatment Drugs market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market play...
The global Viral Testing market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field ...